Evidence map›Paper›PMID 24744580›Full record

ReviewWorld journal of gastroenterology2014

Treatment options in patients with metastatic gastric cancer: current status and future perspectives.

Ahmet Bilici

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. A model established using marital status and other factors from the Surveillance, Epidemiology, and End Results database for early stage gastric cancer.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022
    Article
  16. International journal of biological sciences · 2022
    Article
  17. Article
  18. Article
  19. Review
  20. Patient-reported symptoms in metastatic gastric cancer patients in the last 6 months of life.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Ahmet BiliciAhmet Bilici, Department of Medical Oncology, Medical Faculty, Istanbul Medipol University, Bagcilar, 34214 Istanbul, Turkey.
Istanbul Medipol University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death. As gastric cancer is often diagnosed at an advanced stage, systemic chemotherapy is the mainstay of treatment for these patients. However, no standard palliative chemotherapy regimen has been accepted for patients with metastatic gastric cancer. Palliative chemotherapy including fluoropyrimidine, platin compounds, docetaxel and epirubicin prolongs survival, and improves a high quality of life to a greater extent than best supportive care. The number of clinical investigations associated with targeted agents has recently increased. Agents targeting the epidermal growth factor receptor 1 and human epidermal growth factor receptor 2 (HER2) have been widely tested. Trastuzumab was the first target drug developed, and pivotal phase III trials showed improved survival when trastuzumab was integrated into cisplatin/fluoropyrimidine-based chemotherapy in patients with metastatic gastric cancer. Trastuzumab in combination with chemotherapy was thus approved to be a new standard of care for patients with HER2-positive advanced esophagogastric adenocarcinoma. Thus, the evaluation of HER2 status in all patients with metastatic gastroesophageal adenocarcinoma should be considered. Other agents targeting vascular endothelial growth factor, mammalian target of rapamycin, and other biological pathways have also been investigated in clinical trials, but showed little impact on the survival of patients. In this review, systemic chemotherapy and targeted therapies for metastatic gastric cancer in the first- and second-line setting are summarized in the light of recent advances.

Indexed as

AdenocarcinomaAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCisplatinClinical Trials as TopicDocetaxelEpirubicinErb-b2 Receptor Tyrosine KinasesFluorouracilHumansMedical OncologyNeoplasm MetastasisPalliative CarePyrimidinesQuality of LifeStomach NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCisplatinDocetaxelEpirubicinERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFluorouracilPyrimidinesTaxoidsTrastuzumabVascular Endothelial Growth Factor AAdvanced-stageChemotherapyGastric cancerMetastasisTargeted therapy

Identifiers

PMID24744580
PMCPMC3983446
OpenAlexW2040871044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.